Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Scandinavian Real Heart AB (7820) AI Stock Analysis

1 Followers
DE:7820

Scandinavian Real Heart AB

(Frankfurt:7820)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Focused artificial-heart opportunityRealheart TAH addresses a severe clinical need by targeting patients who may require an alternative to transplantation or other mechanical support. If development and validation succeed, this focused indication could support a differentiated long-term commercialization opportunity.
Negative Factors
Pre-revenue businessRevenue is zero in most years and only a very small base appears in 2022, showing that the company has not established meaningful commercial sales. This leaves the business dependent on successful development, regulatory clearance, and eventual adoption before recurring revenue can emerge.

Scandinavian Real Heart AB (7820) vs. iShares MSCI Germany ETF (EWG)

-60%-50%-40%-30%-20%-10%0%10%20%DE:7820-43.16%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 11.78M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-2.2
Beta (1Y)
-0.04
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
18
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Scandinavian Real Heart AB Business Overview & Revenue Model

Company Description

Scandinavian Real Heart AB (Publ), a Swedish enterprise established in 2007, specializes in the innovation and production of artificial heart devices. The company's core focus is the Realheart TAH, a total artificial heart engineered specifically to...

Scandinavian Real Heart AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:7820 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:GETI.BSE:GETI.B67NeutralSEK 76.26B27.109.13%1.69%-3.90%37.73%
SE:XVIVOSE:XVIVO64NeutralSEK 6.39B50.375.89%―17.83%330.94%
SE:BRAINSE:BRAIN54NeutralSEK 443.05M-12.40-22.23%―0.04%34.45%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:MNTCSE:MNTC51NeutralSEK 450.01M-24.13-15.00%―11.18%60.51%
SE:ACARIXSE:ACARIX45NeutralSEK 211.38M-5.51-96.06%―40.61%32.63%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:7820SE:GETI.BSE:XVIVOSE:ACARIXSE:BRAINSE:MNTCDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:7820 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:7820Scandinavian Real Heart AB1.32-1.01-43.16%
SE:GETI.BGetinge AB (UK)281.6074.4935.96%
SE:XVIVOXvivo Perfusion AB206.0042.5025.99%
SE:ACARIXAcarix AB0.17-0.10-35.42%
SE:BRAINBrainCool AB1.150.61113.81%
SE:MNTCMentice AB16.202.3516.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.